# Atrasentan in Patients With Proteinuric Glomerular Diseases

Study · id `cardio:ct-nct04573920` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04573920](<https://clinicaltrials.gov/study/NCT04573920>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04573920

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 103 participants.

## Technical summary

Registry record NCT04573920. Non-randomized; no masking; primary purpose treatment. Start 2021-03-15 (actual); primary completion 2024-07-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT04573920, source copy `cardio:ctgov-nct04573920-2026-06-01`, retrieved 2026-10-26)
- Started: 2021-03-15 (actual) (ClinicalTrials.gov record NCT04573920, source copy `cardio:ctgov-nct04573920-2026-06-01`, retrieved 2026-10-26)
- Primary completion: 2024-07-02 (actual) (ClinicalTrials.gov record NCT04573920, source copy `cardio:ctgov-nct04573920-2026-06-01`, retrieved 2026-10-26)
- Completion: 2026-10-27 (anticipated) (ClinicalTrials.gov record NCT04573920, source copy `cardio:ctgov-nct04573920-2026-06-01`, retrieved 2026-10-26)
- Countries: United States; Australia; Italy; South Korea; Spain; United Kingdom (ClinicalTrials.gov record NCT04573920, source copy `cardio:ctgov-nct04573920-2026-06-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04573920-2026-06-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atrasentan in Patients With Proteinuric Glomerular Diseases
- Acronym: AFFINITY
- Condition: IgA Nephropathy
- Condition: Focal Segmental Glomerulosclerosis
- Condition: Alport Syndrome
- Condition: Diabetic Kidney Disease
- Condition: Diabetic Nephropathy Type 2
- Condition: Immunoglobulin A Nephropathy
- Intervention (Drug): Atrasentan
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 450080a1fff3a4ffeea4fe71735e1fa04758df3afa8f0f8a5a958b6c70155314
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
